CN1747738B - 缓释抗感染剂 - Google Patents
缓释抗感染剂 Download PDFInfo
- Publication number
- CN1747738B CN1747738B CN2003801065342A CN200380106534A CN1747738B CN 1747738 B CN1747738 B CN 1747738B CN 2003801065342 A CN2003801065342 A CN 2003801065342A CN 200380106534 A CN200380106534 A CN 200380106534A CN 1747738 B CN1747738 B CN 1747738B
- Authority
- CN
- China
- Prior art keywords
- liposome
- amikacin
- infective
- described purposes
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 57
- 208000015181 infectious disease Diseases 0.000 claims abstract description 36
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 33
- 239000002502 liposome Substances 0.000 claims description 144
- 229960004821 amikacin Drugs 0.000 claims description 75
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 75
- 230000002924 anti-infective effect Effects 0.000 claims description 71
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 38
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 34
- 235000012000 cholesterol Nutrition 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 150000008271 glucosaminides Chemical class 0.000 claims description 14
- 238000012545 processing Methods 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 8
- 241000589516 Pseudomonas Species 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 claims description 4
- 241000186359 Mycobacterium Species 0.000 claims description 4
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- 229960001656 amikacin sulfate Drugs 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241001453380 Burkholderia Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 claims description 2
- 241001600125 Delftia acidovorans Species 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000245654 Gladiolus Species 0.000 claims description 2
- 241000606790 Haemophilus Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims description 2
- 241001455333 Mycobacterium fortuitum complex Species 0.000 claims description 2
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 2
- 241000187492 Mycobacterium marinum Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 2
- 241000589776 Pseudomonas putida Species 0.000 claims description 2
- 241000736110 Sphingomonas paucimobilis Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 210000000081 body of the sternum Anatomy 0.000 claims description 2
- 201000004015 melioidosis Diseases 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 4
- 238000000034 method Methods 0.000 abstract description 50
- 201000003883 Cystic fibrosis Diseases 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000000052 comparative effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 73
- 210000004072 lung Anatomy 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 26
- 229960000707 tobramycin Drugs 0.000 description 26
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 26
- 241000700159 Rattus Species 0.000 description 22
- 239000000203 mixture Substances 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 14
- 229960003405 ciprofloxacin Drugs 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 210000003437 trachea Anatomy 0.000 description 12
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 11
- 229940126575 aminoglycoside Drugs 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 206010036790 Productive cough Diseases 0.000 description 8
- -1 albumin Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000003802 sputum Anatomy 0.000 description 8
- 208000024794 sputum Diseases 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000011026 diafiltration Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229940092456 curosurf Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000003578 releasing effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 210000001132 alveolar macrophage Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 230000002045 lasting effect Effects 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 238000003672 processing method Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101150026476 PAO1 gene Proteins 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 239000000039 congener Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 208000023372 inhalational anthrax Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 206010035667 Pneumonia anthrax Diseases 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 2
- 241000190932 Rhodopseudomonas Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960001668 cefuroxime Drugs 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003324 clavulanic acid Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000009449 inhalation anthrax Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000013554 lipid monolayer Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229940067626 phosphatidylinositols Drugs 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960000580 terconazole Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036228 toxication Effects 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 1
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- PYVRVRFVLRNJLY-KTKRTIGZSA-N 1-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-KTKRTIGZSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- OUULBAYKRAOUFC-UHFFFAOYSA-N C(CCCCCCCCCCC)(=O)CCP(O)(O)=O Chemical compound C(CCCCCCCCCCC)(=O)CCP(O)(O)=O OUULBAYKRAOUFC-UHFFFAOYSA-N 0.000 description 1
- TVSDIEHBKKUOCH-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCC(CP(O)(O)=O)CCCCCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCCCCCC(CP(O)(O)=O)CCCCCCCCCCCCCCCCCC TVSDIEHBKKUOCH-UHFFFAOYSA-N 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 1
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 102100036284 Hepcidin Human genes 0.000 description 1
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 206010071401 Mycobacterium chelonae infection Diseases 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920000292 Polyquinoline Polymers 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
- 101100224410 Solanum tuberosum DPEP gene Proteins 0.000 description 1
- 241000145525 Spinach latent virus Species 0.000 description 1
- 235000018087 Spondias lutea Nutrition 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- VZLUMFQKUQQRKH-UHFFFAOYSA-N [I].N1=CC=CC2=CC=CC=C21 Chemical compound [I].N1=CC=CC2=CC=CC=C21 VZLUMFQKUQQRKH-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229950006704 aldesulfone Drugs 0.000 description 1
- NEDPPCHNEOMTJV-UHFFFAOYSA-N aldesulfone Chemical compound C1=CC(NCS(=O)O)=CC=C1S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1 NEDPPCHNEOMTJV-UHFFFAOYSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960000717 carindacillin Drugs 0.000 description 1
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 description 1
- KNIWPHSUTGNZST-SSWRVQTPSA-N colistin B Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O KNIWPHSUTGNZST-SSWRVQTPSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GTDHYNXLIKNVTJ-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NC(C)(C)CO GTDHYNXLIKNVTJ-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- FTMKAMVLFVRZQX-UHFFFAOYSA-N octadecylphosphonic acid Chemical compound CCCCCCCCCCCCCCCCCCP(O)(O)=O FTMKAMVLFVRZQX-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940041024 other aminoglycosides in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 201000008246 pneumonic tularemia Diseases 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 1
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明所提供之一是一种处理或改善囊性纤维变性患者肺部感染的方法,该方法给予患者肺部一种有效剂量的脂质体/复方抗感染剂,其中(i)给药量为相应单方药量的50%或更少,或(ii)剂量为每天一次或更少,或(iii)以上两者。
Description
本申请要求于2002年10月29日提交的美国临时申请60/421,923提交的优先权。
本项缓释技术适用于例如借助脂质体和类脂复合物经吸入方式给药,通过缓释作用、靶向能力及增强病灶部位对药物的吸收对肺和全身提供一种长期的处理效果。本发明包括一种脂质体抗感染剂,以及应用脂质体或类脂复方抗感染剂处理囊性纤维变性(CF)患者肺部感染的方法。意想不到的是,用新配方进行处理所需要的剂量远低于本行业中已知的有效剂量。
就象Goodman和Gilman在“The Pharmaceutical Basis ofTherapeutics”[治疗学的药物基础]第八版中所报道的那样,“自从发现肾毒症及耳毒症的发生与氨基糖苷累集的浓度有关之后,减少肾功能损害患者体内这类药物的滞留剂量就变得极为关键”。由于不管病人是否已存在损伤,氨基糖苷类都能造成前庭或听觉机能失调及肾毒性,因此普遍来讲降低该类药物的滞留剂量非常重要。本发明可显著降低氨基糖苷类的滞留剂量。
囊性纤维变性病人肺里有大量粘液和/或唾沫分泌物、多发伴随性感染以及起源于细菌繁殖的生物被膜。所有这些分泌液和物质均对于抗感染剂有效的靶向抗感染作用造成障碍。本发明可以克服这些障碍,并且可以降低剂量(在数量或频率上),因此可降低药物在病人体内的负荷。
对于一般肺部感染来说,本发明所提供的给药方案提供了一种降低药物负荷的途径。
发明内容
本发明所提供的之一是脂质体/复方抗感染剂的用于制备一种药物的用途,其中所述药物用于处理或改善囊性纤维变性患者肺部感染,包括给予患者肺部一种有效剂量的脂质体/复方抗感染剂,其中(i)给药量为相应单方药量的50%或更少,或(ii)剂量为每天一次或更少,或(iii)以上两者
本发明也提供一种处理或改善患病动物肺部感染的方法,该方法包括给予患病动物肺部包含有效剂量的脂质体/复方抗感染剂,其中(i)给药量为相应单方药量的50%或更少,或(ii)剂量为每2天一次或更少。
附图概述
图1:囊性纤维变性病人痰液/生物被膜的横切面图。
图2:本发明中药物靶向作用及存贮效果的图示。
图3和4:不同形式丁胺卡那霉素的细菌学图示。
图5:脂质体/复方丁胺卡那霉素和妥布霉素缓释作用的图示。
图6:单方或者复方环丙沙星的数据。
图7:使用不同给药方案在肺中药物残留量的图示。
发明的详细描述
本申请揭示一种处理或改善肺部感染的方法,如囊性纤维变性病人的感染,该方法包给药用类脂颗粒胶囊化的抗感染剂(如抗生素)。
抗感染剂是抵抗感染的药剂,例如抗细菌、分支杆菌、真菌、病毒或者原生动物的感染。
本发明中所指的抗感染剂包括但并不仅限于以下几类:氨基糖苷类(如链霉素,庆大霉素,妥布霉素,丁胺卡那霉素,奈替米星,卡那霉素等);四环素类(如金霉素,土霉素,甲烯土霉素,强力霉素,米诺四环素等);磺胺类(如磺胺,磺胺嘧啶,磺胺甲噁唑(sulfamethaoxazole),磺胺异噁唑,磺醋酰胺等);对-氨基苯甲酸,二氨基嘧啶(如甲氧苄啶等,常与磺胺甲噁唑、吡嗪酰胺等联合使用);喹诺酮类(如萘啶酸,西诺沙星,环丙沙星和氟哌酸等);青霉素类(如青霉素G,青霉素V,氨苄西林,阿莫西林,巴氨西林,羧苄西林,卡茚西林,替卡西林,阿洛西林,美洛西林,哌拉西林等);耐青霉素酶青霉素(如甲氧苯青霉素,苯甲西林,氯唑西林,双氯青霉素,萘夫西林等);第一代先锋霉素类(如头孢羟氨苄,头孢氨苄,头孢菌素,先锋霉素,头孢匹林,头孢唑林等);第二代先锋霉素类(如头孢克洛,头孢羟唑,头孢尼西,头孢西丁,头孢替坦,头孢呋辛,头孢呋肟酯,头孢美唑,头孢罗齐,氯拉卡比,头孢胺四唑等);第三代先锋霉素类(如头孢平,头孢哌酮,氨噻肟头孢菌素,头孢去甲噻肟,头孢曲松,头孢他定,头孢克肟,头孢泊肟,头孢布坦等);其他β-内酰胺类(如亚胺培南,美罗培南,氨曲南,克拉维酸,舒巴克坦,三唑巴坦等);β-内酰胺酶抑制剂(如克拉维酸酸),氯霉素,大环内酯类(例如红霉素,阿奇霉素,克拉霉素等);林可霉素,氯林可霉素,大观霉素,多粘菌素B,多聚喹碘(例如多粘菌素A,B,C,D,E1(粘菌素A)或E2,粘菌素B或C等),粘菌素,万古霉素,杆菌肽素,异烟肼,利福平,乙胺丁醇,乙硫异烟胺,氨基水杨酸,环丝氨酸,卷曲霉素,砜类(如氨苯砜,亚磺氨苯砜钠等),氯法齐明,沙利度胺,或其它任何可以进行类脂胶囊化的抗菌制剂。抗感染剂可以包括抗真菌剂,包括多烯抗真菌剂(如两性霉素B,制霉菌素,那他霉素,及其它同类物),氟胞嘧啶,咪唑类(如咪康唑,克霉唑,益康唑,酮康唑,及其它同类物),三唑类(如伊曲康唑,氟康唑,及其它同类物),灰黄霉素,特康唑,环吡酮布康唑,环吡酮胺,卤普罗近,托萘酯,萘替芬,特比萘芬,或其它任何可以进行类脂胶囊化或复方化的抗真菌制剂。在讨论及实施例中主要是指丁胺卡那霉素,但本申请范围并不仅限于这种抗感染剂。也可以使用联合药物。
特别优选的抗感染剂包括氨基糖苷类,喹诺酮类,多烯抗真菌剂以及多粘菌素类。
在肺感染中(如在囊性纤维病人中),可用本发明的方法处理的有假单胞菌属(例如绿脓假单胞菌,少动假单胞菌,恶臭假单胞菌,萤光假单胞菌,食酸假单胞菌),葡萄球菌,耐甲氧苯青霉素金黄色葡萄球菌(MRSA),链球菌(包括肺炎链球菌),大肠杆菌,克雷伯氏菌属,肠杆菌属,沙雷氏菌,嗜血杆菌属,鼠疫耶尔森(氏)菌,类鼻疽伯克霍尔德氏菌,洋葱(cepacia)伯克霍尔德氏菌,唐菖蒲(gladioli)伯克霍尔德菌,multivorans伯克霍尔德氏菌,越南(Vietnamiensis)伯克霍尔德氏菌,结核分支杆菌,鸟分枝杆菌复合体(MAC)(鸟分枝杆菌和细胞内分枝杆菌),堪萨斯分枝杆菌素,蟾蜍分枝杆菌,海分枝杆菌,溃疡分枝杆菌,偶发分枝杆菌复合物(偶发分枝杆菌和龟分枝杆菌)感染。
在本发明的一个实施例中包括一种服用脂质体/复方丁胺卡那霉素的处理方法。
这里所讨论的“脂质体或类脂复方”抗感染剂,或“脂质体/复方”抗感染剂,或“Lip-抗感染剂”,或“Lip-An”是抗感染剂组份的任何形式,其中至少抗感染剂重量的1%与类脂相关联,其可以是与类脂复合物的一部份,或作为一种脂质体,该脂质体中的抗生素可以在液相中或脂质双层的疏水相中、或位于脂质体双层界面中间的头部(headgroup)区。优选地,至少5%,或至少10%,或至少20%,或至少25%是具有这种关联性的。这种关联通过过滤器进行分离而测量,其中类脂或类脂相关联药物存留而单方药剂在滤出液中。
利用脂质体/复方抗感染剂处理较以前已知的处理方法所需的剂量明显降低。在一个优选的实施方案中,人的服药剂量为每天低于100mg氨基葡糖苷。在另一个优选的实施方案中,每2天或每3天服药约30~50mg。与其它非脂质体或类脂复合物抗感染剂所推荐使用的剂量进行比较,预计脂质体/复方抗感染剂在其它动物中所使用的剂量也应该相应地降低。这是一种意料之外的低剂量。
对于下述没有提供特定剂量的那些,本发明中优选的剂量是最低单方药量(当然可以是其盐类)的50%或更低、35%或更低、20%或更低、或10%或更低。如果是通过喷雾器将药物传送到肺部,则在14天的疗程后,可以使肺中菌落形成单位(CFU)降低一个数量级。相对的单方药量是可用于本发明服药疗程中的累积药量。在本章中所定义的相对的最低单方药量是“相对单方药量”。
尽管本发明的实施方案优选的是用于人类,但其中非囊性纤维变性的处理实施方案也适用于任何动物。对某种特定的动物所使用的相应剂量可根据不同的动物进行测量。
优选的给药方案是每天一次或更少。在优选的实施方案中,给药方案是隔天、每3天、每周一次或更少。例如,给药方案可以是隔天一次或更少,采用的剂量为相应单方剂量的50%或更少。或者,例如给药也可以每天一次,剂量为相应单方剂量的35%或更少。
为处理本发明中所指的感染,临床医生将使用一种有效数量的药物,而这种有效数量应达到处理、减轻、改善、消除或者预防需要处理的疾病或需要防御或处理的病症的一种或多种症状,或者能对疾病或病症的病理产生临床可识别的改变。“改善”包括降低需防治的动物感染的发病率或严重程度。在特定的实施方案中,有效剂量指可以在肺部感染症状出现后,能够处理或改善症状的剂量。在其他特定的实施方案中,有效剂量指能够处理或改善需防治的动物感染的平均发病率或严重程度(如统计学研究的测量结果)。
基于脂质体或者其他类脂的传递系统可以以喷雾、粉状或气溶胶的形式进行吸入,或者以鞘内方式给药。优选的给药途径为吸入法。与单方或母方形式相比,该剂型的总结果是给药频率的减少及处理指数的增加。脂质体或者脂质复合物具有很大的优势,这是由于它们与肺纹理或肺表面活性物质具相容性,对药物具保护作用。
本发明包括处理肺革兰氏阴性菌感染的方法。一种普遍处理的感染是囊性纤维变性病人的慢性肺部感染。已知利用丁胺卡那霉素处理肺部感染(如囊性纤维变性病人)的方法是通过吸入法每天给予大约200-600毫克丁胺卡那霉素或者四环素。在本发明的一个实施方案中,处理方法是每天给予100毫克或更低的丁胺卡那霉素(如果服药频率低,可标准化为每天给予100毫克或更低的量)。在另一个实施方案中,处理方案为每天给予60毫克或者更少的丁胺卡那霉素。在又一个实施方案中,采取的是每2天给药不多于一次,每次大约30-50毫克。最优选的实施方案包括每隔一天或者每3天给药约30-50毫克。
已知利用妥布霉素处理成人及6岁或6岁以上儿童肺部感染的方法,一般药量为300毫克,每天2次。在本发明的一个优选的实施方案中,处理方法是每天服用100毫克或更少的妥布霉素。在另一个实施方案中,实施的是每天服用60毫克或更少的妥布霉素。在又一个实施方案中,采取的是2天给药不多于一次,每次大约30-50毫克。最优选的实施方案包括每隔一天或者每3天给药约30-50毫克。
在本发明的配方中所使用的类脂可以是合成的、半合成的或者天然类脂,包括磷脂类、维生素E、类固醇、脂肪酸、糖蛋白类如白蛋白、阴性类脂和阳性类脂。磷脂类包括卵磷酸卵磷酯(EPC)、卵磷脂酰甘油(EPG)、卵磷脂酰肌醇(EPI)、卵磷脂酰丝氨酸(EPS)、磷脂酰乙醇胺(EPE)和卵磷脂酸(EPA);大豆的类似物,大豆磷酸卵磷酯(SPC);SPG,SPS,SPI,SPE,和SPA;氢化的蛋类和大豆类似物(例如,HEPC,HSPC);由甘油中2、3位脂肪酸的酯键所组成的包含12-26个碳原子的其他磷脂,以及由甘油中第1位的不同首基(head group)所组成的磷脂,包括胆碱、甘油、肌醇、丝氨酸、氨基乙醇、以及相应的磷脂酸。这些脂肪酸的碳链可以是饱和的或者不饱和的,而磷脂可以由不同碳链长度及不同饱和度的脂肪酸所组成。尤其是配方的成份中可包含一种二棕榈酰磷脂酰胆碱(DPPC),它像二油醇磷酸卵磷酯(dioleoylphosphatidylcholine)(DOPC)一样,是天然的肺表面活性剂的一种重要成份。其他成份还包括二肉豆蔻酰磷脂酰胆碱(DMPC)、以及二肉豆蔻酰磷脂酰甘油(DMPG)、二棕榈酰磷脂酰胆碱(DPPC)、和二软酯酰卵磷酯(DPPG)、二硬脂酰卵磷脂(DSPC)、二硬脂酰卵磷酯(DSPG)、dioleyl-脑磷酯(DOPE)、以及混合磷脂如棕榈酰硬脂酰磷酸卵磷酯(palmitoylstearoylphosphatidylcholine)(PSPC)和棕榈酰硬脂酰磷脂酰甘油(palmitoylstearoylphosphatidylglycerol)(PSPG)、(PSPG)、三酰基甘油、二酰基甘油、seranide、鞘氨醇、鞘磷脂和单酰化磷脂如单-油酰基-脑磷酯(MOPE)。
所使用的类脂可以包括铵盐脂肪酸、磷脂类和甘油酯、类固醇、磷脂酰甘油(PGs)、磷脂酸(PAs)、磷脂酰肌醇(PCs)、磷脂酰肌醇(Pls)和磷脂酰丝氨酸(PSs)。脂肪酸包括饱和或不饱和的碳链长度为12-26个碳原子的脂肪酸。某些特例包括:肉豆蔻胺、十六胺、月桂胺和硬脂酰胺、二月桂酰乙基磷酸胆碱(DLEP)、二肉豆蔻酰乙基磷酸胆碱(DMEP)、二棕榈酰乙基磷酸胆碱(DPEP)和二硬脂酰乙基磷酸胆碱(DSEP),氯化N-(2,3-二(9(Z)十八烯基氧(octadecenyloxy))-丙(prop)-1-基-N,N,N-三甲基铵(DOTMA)和1,2-双(油酰氧基)-3-(三甲铵)丙烷(DOTAP)。类固醇包括胆固醇和麦角固醇。PGs,PAs,PIs,PCs和PSs包括DMPG,DPPG,DSPG,DMPA,DPPA,DSPA,DMPI,DPPI,DSPI,DMPS,DPPS和DSPS,DSPC,DPPC,DMPC,DOPC,以及卵PC。
由磷酸卵磷酯(如DPPC)所组成的脂质体或类脂复合物可以协助肺内细胞如肺泡巨噬细胞吸收药物,并且能帮助肺内抗感染剂的持续释放(Gonzales-Rothi et al.(1991))。阴性类脂(例如PG,PA,PS和PI,)除能够减少粒子聚集之外,还在吸入剂组份的缓释及组份在肺内的运输(胞吞转运作用(transcytosis))以使全身吸收中起作用。人们认为甾醇类化合物能影响药物组份的释放及渗漏特性。
脂质体是内含液相容积的完全闭合的类脂双层膜。脂质体可以是单层囊泡(含单个的双层膜)或者多层囊泡(含多个双层膜的典型的洋葱样结构,相互之间由一液体层分隔)。双层膜由两个脂质单层所组成,每个单层含一疏水性的″尾″区和一亲水性的“头”区。双层膜的结构是:疏水性(非极性)“尾”区类脂单层朝向脂质双层膜的中央,而亲水性的“头”部朝向双层膜的水相。类脂复合物是类脂和掺入的抗感染剂之间的联系物。这种联系可以是共价的、离子的、静电的、非共价的或立体的。这类复合物是非脂质体,并且不会捕获多余的水溶性溶解物。这类复合物的例子包括两性霉素B的类脂复合物(Janoff等,Proc.Nat Acad.Sci.,85:61226126,1988)以及心肌磷脂与阿霉素的复合物。
类脂包合物是一种三维的、笼子一样的结构,包含一种或多种类脂,这种结构可以捕获一种具生物学活性的试剂。这样的包合物属于本发明的范畴之内。
脂质体前体是当与某种水溶性液体接触时可形成脂质体或者类脂复合物的组份。搅拌或者其它混合方式是必需的。这样的脂质体前体属于本发明的范畴之内。
脂质体可由多种方法制备(如见,Bally,Cullis等.BiotechnolAdv.5(1):194,1987).Bangham的操作(J.Mol.Biol.,J Mol Biol.13(1):238-52,1965)制备普通的多层囊泡(MLV).Lenk等(美国,专利号分别为4,522,803、5,030,453和5,169,637),Fountain等(美国,专利号为4,588,578)以及Cullis等(美国,专利号为4,975,282)揭示了制备多层脂质体的方法,在其每层液体隔层里有大致相等的层间溶质分布。Paphadjopoulos等在,(美国,专利号为4,235,871)中揭示了通过反相蒸发法制备寡层脂质体的方法。
单层囊泡可以通过多种技术经MLV产生,例如,Cullis等(美国,专利号为5,008,050)以及Loughrey等(美国,专利号为5,059,421)的挤压法。可以利用声裂法和匀浆化从大的脂质体生产较小的单层脂质体(见,例如,Paphadjopoulos等,Biochim.Biophys.Acta.,135:624-638,1967;Deamer,美国,专利号为4,515,736;以及Chapman等,Liposome Technol.,1984,pp.1-18)。
Bangham等(J.Mol.Biol.,1965,13:238-252)最初制备脂质体的方法包括将磷脂悬浮到一种有机溶剂中,随后蒸发至干,在反应容器中留下一层磷脂膜。然后加入适量的水相,使混合物进行″膨胀″,所产生的包含多层脂囊(MLV)的脂质体通过机械方法进行分散。这种制备法为Papahadjopoulos等(Biochim.Biophys,Acta.,1967,135:624-638)所描述的通过声波处理生产小单层囊泡及大单层囊泡的方法提供了基础。
生产大的单层囊泡(LUV)的技术如反相蒸发法、注入过程和清洁剂稀释,均可应用于生产脂质体。对这些方法的综述以及生产脂质体的其他方法见“脂质体”,Marc Ostro,等,Marcel Dekker公司,NewYork,1983,第1章,其有关部分在这里被引为参考文献。也可见Szoka,Jr.等.,(1980,Ann.Rev.Biophys.Bioeng.”,9:467),其有关部分在这里也被作为参考文献。
其它用于制备囊泡的方法包括那些能形成反相蒸发囊泡(REV)的方法(Papahadjopoulos等.,美国,专利号4,235,871)。另一类可利用的脂质体是那些具有大致相同溶质层分布特点的脂质体。这类脂质体被Lenk等在美国专利4,522,803中命名为稳定的多层囊泡(SPLV),并包括Fountain等在美国专利4,588,578中所描述的单相囊泡以及以上所描述的冷冻和融解的多层囊泡(FATMLV)。
多种甾醇及其水溶性衍生物例如胆固醇和半琥珀酸酯已经被用于制备脂质体;特别见于Janoff等,美国专利4,721,612,1988年1月26日出版,题目为“甾族脂质体”。Mayhew等描述了一种减少抗细菌制剂及抗病毒制剂毒性的方法,该方法利用含α-生育酚及其特定衍生物的脂质体将上述药剂胶囊化。此外,多种生育酚及其水溶性衍生物也被用于制备脂质体,见Janoff等美国专利号5,041,278。
形成脂质体或者类脂复合物的过程涉及一个″溶剂注入″的过程。该过程包括在少量的(优选最少量的)过程合适的溶剂里溶解一种或多种类脂,以形成类脂悬浮液或溶液(优选溶液),然后将该溶液注入到含生物活性制剂的水溶性介质中。典型的过程合适溶剂是能够通过例如透析之类的过程清洗掉的溶剂。进行冷/热循环的组合物优选通过溶剂注入而形成,优选的为乙醇注入。优选的溶剂为酒精。“乙醇注入”是溶剂注入过程的一种,即在少量的(优选最少量的)的酒精里溶解一种或多种类脂,以形成类脂溶液,然后将该溶液注入到含生物活性制剂的水性介质中。“少”量溶剂是指在注入过程里可以形成脂质体或者类脂复合物的合适的量。该过程可见于以下的文献中Lee等,美国专利申请10/634,144,2003年8月4日提交;Pilkiewicz等,美国专利申请10/383,173,2003年3月5日提交;以及Boni等,美国专利申请10/383,004,2003年3月5日提交。以上申请在此全部被引为参考文献。
脂质体或脂质复合物的分筛可以由多种方法完成,本行业熟练技术人员非常熟悉并且普遍使用的方法如挤压法、声裂法和匀浆法。挤压法是将脂质体在一定的压力下,用规定孔径大小的滤器进行一次或多次过滤。滤器通常是由聚碳酸酯制造的,但也可以由其它任何耐用材料制备,只要该材料不与脂质体相互反应,而且在挤压时能耐足够的压力即可。优选的滤器包括“直线滤过”型滤器,因为该滤器一般能承受本发明中优选的挤压过程所需的高压。也可以使用“弯曲型”滤器。挤压法也可以使用非对称的滤器,如AnotecOTM滤器,该滤器涉及通过一种多孔径的分支型氧化铝滤器挤压脂质体。
脂质体或类脂复合物也可以用声裂法进行分筛,该方法是利用声波的能量破裂或剪切脂质体,可以使其自然形成更小的脂质体。声裂法是通过将含有脂质体悬液的玻璃管浸入到一种震动的声波中,该声波由一种“浴室型”的超声破碎器产生。或者也可以使用一种探头型的超声破碎器,其声波能量是通过钛探头与脂质体悬液的直接接触时的震动而产生的。匀浆法及研磨仪如Gifford Wood匀浆器、Poltron或MicrofluidizerTM也可用来将大的脂质体或类脂复合物破碎成小的脂质体或类脂复合物。
所形成的脂质体/复合物可以使用在本行业中所熟知的方法分散成均质物;例如正切流动过滤。在这个过程中,大小不同的异质脂质体或类脂复合物流过正切流动过滤器,从而形成具有上限和/或下限尺寸大小的脂质体聚合物。当使用两种具有不同孔径的过滤器时,直径小于第一种过滤器孔径的脂质体可以通过该过滤器。该滤液可通过第二种过滤器进行正切流动过滤,第二次过滤的孔径小于第一次。这种过滤器的产物是具有第一和第二种过滤器所分别规定的上下限孔径大小范围之内的脂质体/复合物的聚合体。
Mayer等发现可以利用跨膜离子梯度来解决与亲脂性的、可电离的生物活性制剂的有效捕获相关的问题,如蒽环类抗生素或长春花碱类等抗肿瘤制剂。该类跨膜梯度除了可诱导更有效的捕获外,还能增加抗感染剂在脂质体/复合物中的滞留。
脂质体/复方抗感染剂具有持续的抗感染效果及较低的毒性,因此可以减少给药频率并提高处理指数。在临床前的动物实验中,与同等剂量的吸入性妥布霉素(并非脂质体或者类脂复方)相比,脂质体/复方丁胺卡那霉素在给药后不久直至给药24小时后,在肺内的药物水平是妥布霉素的二到几百倍之多。另外,脂质体/复方丁胺卡那霉素可将这种药效保持到超过24个小时。在用于模拟囊性纤维变性病人中可见的假单胞菌感染的动物模型中,与单方氨基糖苷类比较,脂质体/复方丁胺卡那霉素可明显减轻动物的肺部感染。
肺表面活性剂使得肺在呼吸时可以扩张和收缩。这种作用可以通过用类脂和蛋白质的组合物涂敷肺来完成。类脂呈现的是一种单层,其疏水性碳链朝向外侧。类脂占肺表面活性剂的80%,类脂的主要成份为磷脂酰胆碱,其中50%为二棕榈酰磷脂酰胆碱(DPPC)(Veldhuizen等,1998)。表面活性蛋白(SP)的功能是维持表面活性剂的结构,并协助呼吸时肺表面活性剂的扩张和收缩。在这些蛋白中,SP-B和SP-C尤其具有溶解特性,可以溶解脂质体(Hagwood等,1998;Johansson,1998)。人们相信这种溶解特性可以促进随后对脂质体的连续分解,并通过释放其内容物而发挥一种存贮作用。这种脂质体的分解自然发生,可通过自然裂解由细胞外排作用所排出的板层状小体所证实(Ikegami&Jobe,1998)。脂质体除了可由肺表面活性剂所同化,也可由巨噬细胞通过吞噬作用直接进行消化(Couveur等,1991;Gonzales-Roth等,1991;Swenson等,1991)。肺泡巨噬细胞对脂质体的摄取是药物传递到病灶部位的另一种方法。
优选的用来形成吸入性脂质体或脂质复合物的类脂,与发现于肺表面活性剂中的内源性类脂类似。脂质体由双层膜组成,可以捕获所需的药剂。这些同心双层可构成多层脂囊,其中药剂可捕获于不同层的类脂之内或层与层之间的液相空间中。本发明使用独特的方法生产独特的脂质体和脂质体/药物复合物。这些方法和该类方法的产品都是本发明的一部分。
用于本发明中优选的类脂与药剂的比率是小于3比1。更优选的类脂与药剂的比率是小于2.5比1。此外,产品在透析一段时间之后,其中游离的抗感染剂的比例会降低。
这里所描述的全部方法均很容易适用于大规模及无菌生产。最终脂质体的大小可以通过修改类脂的组成、浓度、辅料及加工的参数进行调整。
处理例如绿脓假单胞菌那样的传染病的一个障碍是药物在上皮细胞的痰液/生物被膜屏障内部的渗透(图1),绿脓假单胞菌是造成囊性纤维变性患者慢性疾病的首要原因。在图1中,环形表示脂质体/复方抗感染剂,符号″+″表示单方抗感染剂,符号″-″表示粘蛋白、藻酸盐和DNA,实心条符号表示绿脓假单胞菌。这种屏障由包埋于藻酸盐中的集落型和浮游的绿脓假单胞菌或来源于细菌的胞外多糖,以及来源于破损的粒细胞中的DNA和肺上皮细胞中的粘蛋白所组成,以上物质均含负电荷(Costerton,等,1999)。这些负电荷相互结合,并且阻止带正电荷的药物(例如氨基糖苷类)的渗透,使其生物学功能失效(Mendelman等,1985)。将抗感染剂捕获于脂质体或者类脂复合物中,可以屏蔽或者部分屏蔽抗感染剂与痰液/生物被膜的非特异性结合,从而使脂质体或者类脂复合物(内含氨基葡糖苷)可以进行渗透(图1)。
研究发现丁胺卡那霉素对细菌酶具有高度抵抗力,因此能比其它氨基糖苷类包括妥布霉素和庆大霉素处理更大比例的临床敏感分离株(Price等,1976)。尤其是绿脓假单胞菌分离株对丁胺卡那霉素的敏感性远大于其他氨基糖苷类(Damaso等,1976)。
从图2中可清楚地看出脂质体/复方丁胺卡那霉素的缓释效应及存贮效应。在该研究中,大鼠通过气管和静脉途径给予妥布霉素,也通过气管途径给予相同剂量(4毫克/每只大鼠)的脂质体/复方丁胺卡那霉素。数据显示,只有脂质体/复方丁胺卡那霉素能达到缓释及存贮效果。事实上,在给药后24小时,只有脂质体/复方丁胺卡那霉素在动物肺内具有明显的药量,而两种妥布霉素配方均显示阴性水平,主要原因是全身的快速吸收。这种脂质体/复方抗感染剂能使氨基葡糖苷在肺中增加100倍以上,这种现象支持具缓释效果的脂质体/复方抗感染剂的服药频率可以远低于现在通用的TOBITM配方(Chiron公司,AMERYVILLE,CA)的观点。
而且,由于痰液/生物被膜的表面与抗感染剂结合,其存在能阻碍单方氨基糖苷类的渗透(图1)。因此,妥布霉素的剂量在超过1000μg/克肺组织时才能在囊性纤维变性病人中具有处理效果。而脂质体/复方丁胺卡那霉素能克服这一缺点。因此,与单方妥布霉素比较,脂质体/复方丁胺卡那霉素药效的持续时间要长得多。这种结合与渗透的简易性也可以作为一种方法,利用此方法脂质体/复方丁胺卡那霉素可显著降低细菌的耐药性,而这种耐药性在体内的抗菌药物剂量低于最低抑制浓度时经常出现。
丁胺卡那霉素的药物动力学是在大鼠中以气管内(IT)给予单方妥布霉素或者脂质体/复方丁胺卡那霉素之后确定的。这些数据是与尾静脉注射单方妥布霉素后药物在肺部的分布进行比较的。在所有的实验中,给药剂量为4mg/只大鼠。正如在图2所见的一样,与注射相比,气管内给药所传送的氨基葡糖苷的数量要大得多。脂质体/复方抗感染剂技术与气管或静脉给予妥布霉素所产生的贮存效果相比,在给药后24小时,脂质体/复方丁胺卡那霉素在肺中的药量提高同样在100倍以上。因此,与单方妥布霉素相比,脂质体丁胺卡那霉素配方中药物处理水平的持续时间要长。
特别是当氨基糖苷类与囊性纤维变性病人痰液的结合导致抗感染剂生物活性的降低时,这种结合成为人们关心的问题(Hunt等,1995)。为确定脂质体/复方丁胺卡那霉素是否能长时间保留生物学活性,通过气管内滴注法给予正常大鼠脂质体/复方丁胺卡那霉素。然后分别在2小时或24小时通过支气管肺泡灌洗(BAL)移出药物,以确定其生物学活性。样品通过超滤及随后的过滤(0.2微米)进行浓缩,以去除所污染的肺部微生物。丁胺卡那霉素浓度的确定采用TDX仪,而其生物学活性利用米勒·欣顿(Mueller Hinton)肉汤稀释分析(绿脓假单胞菌)进行测定。结果见以下的表1。
如上表所示,在给药24小时后,所获得的过滤的脂质体/复方丁胺卡那霉素在米勒·欣顿肉汤分析中仍能杀死绿脓假单胞菌,最低抑菌浓度为4。在2小时所得到的MIC是2,该结果与过滤的脂质体/复方丁胺卡那霉素贮存液类似。因此,脂质体/复方丁胺卡那霉素在肺里24个小时后仍具有活性。24小时时,相同剂量的单方妥布霉素在支气管肺泡灌洗液中已检测不到。这表明脂质体/复方抗感染剂配方不仅在肺中持续存在,而且可以长时间有效渗透痰液/生物被膜。这些数据与图2和表II(在下面)的事实结合起来表明,脂质体/复方丁胺卡那霉素在长时间释放单方抗感染剂的同时,在肺里也能长期维持高水平的抗感染剂,这种现象支持该系统可长时间产生缓释效果的理论。这种效果应当能显著降低假单胞菌属的生物负荷及由于抗感染剂水平降低产生的耐药性。
作为体外演示脂质体/复方丁胺卡那霉素的缓释作用及其持续抗感染效果的实验,将该配方与患者的痰液共同培养,患者具有含PAO1株粘液样假单胞菌的慢性阻塞性肺疾病(COPD)。脂质体/复方丁胺卡那霉素也与含PAO1株粘液样假单胞菌的藻酸盐共培养。在两种情况下,均观察到对假单胞菌长期持续的、增强的杀灭作用,如表II中所示:
经典杀菌曲线不适用于脂质体/复方抗感染剂技术,这是因为脂质体配方具有缓释作用及促进抗感染的效果。直至丁胺卡那霉素的释放,脂质体/复合物能保护该药物免受痰液及藻酸盐的破坏。丁胺卡那霉素释放时,能观察到对细菌完全的杀灭效果,这与缓释及持续抗感染模型是一致的,不存在对抗感染剂的干扰或灭活作用。
用一种慢性肺部感染模型来研究脂质体/复方丁胺卡那霉素的有效性(Cash等,1979)。该模型是将包埋于琼脂糖小球基质中的绿脓假单胞菌滴入到大鼠的气管中。建立这种粘液样假单胞菌动物模型是为了模仿囊性纤维变性病人中所见的假单胞菌感染。与囊性纤维变性临床特征相关的包括:相似的肺病理学;免疫复合物紊乱的出现;以及由绿脓假单胞菌菌株所产生的粘液样表型转化(Cantin和Woods,1999)。用分离于囊性纤维变性病人中的大于107菌落形成单位(CFU)的粘液样假单胞菌(PAO1株)感染大鼠肺,然后分别用以下配方进行处理:(a)单方氨基葡糖苷(b)作为非药物对照的类脂载体本身(c)脂质体/复方丁胺卡那霉素。另外,首先在改进的Kirby-Bauer培养皿上对以上不同配方体外杀灭绿脓假单胞菌的能力进行了筛选。
各种脂质体/复方丁胺卡那霉素配方的测试是基于其不同的类脂组成或不同的生产参数,导致在体外实验中不同的杀灭区域。本实验的设计是为了确定脂质体/复方氨基葡糖苷相对于单方氨基葡糖苷药效的增加。将空白对照类脂组份、两种不同的脂质体/复方丁胺卡那霉素配方、单方丁胺卡那霉素和单方妥布霉素进行了比较,单方药剂中的氨基葡糖苷与脂质体/复方抗感染剂配方中的浓度相同。另外,也采用了10倍高剂量的单方丁胺卡那霉素和10倍高剂量的单方妥布霉素。药物以气管内方式给药,时间为7天以上。结果(图3)表明,两种配方的脂质体/复方丁胺卡那霉素(类脂组成不同)可以显著减少CFU水平,其减少CFU的能力高于10倍剂量的单方丁胺卡那霉素和单方妥布霉素。在图中,Lip-An-14是指DPPC/Chol/DOPC/DOPG(42∶45∶4∶9)以及10mg/ml丁胺卡那霉素,Lip-An-15是DDPC/Chol(1∶1)也为10mg/ml。在此,所有的类脂-类脂和类脂-药物均以重量表示。
下一个实验(图4)是用于证实脂质体/复方丁胺卡那霉素的缓释作用及其持续的抗感染能力。给药剂量是每隔一天一次共14天,作为与前面实验中每天一次共7天的比较。结果表明,与单方丁胺卡那霉素或单方妥布霉素比较,两种配方中的脂质体/复方丁胺卡那霉素(类脂组成不同)的效果均增加10-100倍(减少CFU水平的能力更高)。人每日剂量600毫克(或者大约375毫克/平方米)相当于大鼠每日剂量9.4毫克。因此数据可以直接对应于在病人中增加效果10到100倍。应当指出的是,在该模型中,可观察到的最佳效果是两个对数的减少。在唾沫分析中,绿脓假单胞菌100倍的降低可对应于肺功能的改进(Ramsey,等1993)。脂质体/复方丁胺卡那霉素配方的缓释效果表明,与单方氨基葡糖苷比较,复方低剂量和/或低频率给药可以更好地抑制细菌的生长。
在一个慢性肺部感染模型中研究了脂质体/复方丁胺卡那霉素的效果,该模型是将包埋于琼脂糖小球基质中的绿脓假单胞菌通过气管滴入到Sprague/Dawley大鼠中。3天后,开始每天给予单方丁胺卡那霉素或者脂质体/复方丁胺卡那霉素(图3)或者每隔一天给药(图4),剂量按氨基葡糖苷的量计算为1毫克/大鼠或者10毫克/大鼠,按脂质体/复方丁胺卡那霉素计算为1毫克/大鼠,空白脂质体(类脂载体)为对照,每组5只大鼠。
对实验进行14天后的大鼠肺(冷冻)均化后分析氨基葡糖苷的含量及活性。用TDX仪进行临床化学分析,通过涂布枯草芽孢杆菌的琼脂平板测量抑菌区进行生物活性分析。
结果示于表III。
药品重量为没有任何盐的形式进行标准化。
表ⅡI结果表明,在两种脂质体/复方抗感染剂配方中均存在氨基葡糖苷,且具有活性,而单方氨基葡糖苷即使在10倍剂量时也检测不到。这些结果更进一步明确了脂质体/复方抗感染剂的缓释特性,而且也证实剩余的抗感染剂仍然具有活性。在上述配方中,只有单方妥布霉素(0.1μg/ml)在肾中具有可检测的氨基葡糖苷水平。
脂质体/复方丁胺卡那霉素的缓释及存储效应在图5中进一步得到了展示。利用与检测药效时相同的琼脂糖小球,通过气管滴注包被于琼脂糖小球基质内的绿脓假单胞菌,造成大鼠慢性肺部感染,然后以相同剂量(2毫克/大鼠)通过气管内给予大鼠单方妥布霉素或者脂质体/复方丁胺卡那霉素(配方Lip-An-14)。以微克抗感染剂/每克肺组织进行测量所得的数据显示,脂质体/复方抗感染剂具有缓释及存储效果,而单方妥布霉素在24个小时时肺中已检测不到药物,其主要原因估计是全身的快速吸收。大鼠肺中脂质体/复方抗感染剂这种100倍以上抗感染效果的增加,支持缓释的脂质体/复方抗感染剂较现在通过的TOBITM配方服药频率可以明显减少的观点。
丁胺卡那霉素的药物动力学是用大鼠如下测定的,在大鼠中通过气管内(IT)给予单方妥布霉素或者脂质体/复方丁胺卡那霉素。剂量采用的是2毫克/大鼠。脂质体/复方抗感染剂技术的储存效果是通过与气管内给予单方妥布霉素进行比较来证实的,给药后24小时,感染肺中脂质体/复方丁胺卡那霉素仍具有100倍以上的药量。因此,与单方妥布霉素相比,脂质体配方中药物处理水平的持续时间要长。
图7显示抗感染剂在肺中显著的滞留时间及药效累积效应,该结果证实可采用相对较低的服药频率。每次剂量是4小时,通过吸入法(在大鼠中,每组3只大鼠,如上)给予雾状的脂质体丁胺卡那霉素(1∶1的DPPC/Chol.),15mg/ml的丁胺卡那霉素。给药分别是在第1天、3天和5天;或第1天、2天、3天、4天和第5天。标有数据符号的大鼠分别在服药后被处死。使用的配方与实施例中一致。
类似的抗感染剂可用于处理细胞内感染如肺炭疽和土拉菌病。在肺炭疽中,炭疽芽孢通过气溶胶到达肺泡。所吸入的芽胞由肺泡中的肺巨噬细胞所吞噬,并将其携带到局部气管支气管淋巴结或通过淋巴系统运到纵隔淋巴结(Pile等,1998;Gleiser等,1968)。巨噬细胞既是感染途径的重要部分,又是全身吸入性炭疽宿主自毁的主要参与成份。脂质体/复方抗感染剂技术除协助缓释及靶向以外,还可以增强细胞对药物的吸收,也可以利用肺泡巨噬细胞及肺上皮细胞进行药物的靶向及传递。拥有这些特性被认为有利于处理这类细胞内感染,这类感染发生于肺部而且是由巨噬细胞转运的。更重要的是:这些特性使得含有疾病因子的细胞可以吞噬脂质体/复方抗感染剂,从而使其抗感染效果更强。抗感染剂将以靶向作用的方式在细胞内释放,因此在其扩散之前,即可以发挥其抗感染的作用。这种胶囊化的药物可以是已经经过认证的药物,如环丙沙星,四环素,erthyromycin或者丁胺卡那霉素。已经研发了脂质体/复方环丙沙星。
在一项研究中,给小鼠服用上述复合药物,与气管内给予单方环丙沙星和口服环丙沙星进行了比较,三种药物的给药剂量相同(图6)。每只小鼠的剂量是15毫克/千克,每组3只小鼠。脂质体/复方环丙沙星的配比是二棕榈酰磷脂酰胆碱/胆固醇为9∶1,环丙沙星的量是3mg/ml,该配方的生产与实施例中的一致。药物与类脂的比率是12.5∶1的重量比。与口服环丙沙星相比,脂质体/复方环丙沙星比单方环丙沙星在肺中的药量高出两个数量级。而且,只有脂质体/复方环丙沙星在24个小时之后在肺里仍可检测到,而口服药剂在不到两小时即无法检测。该数据证实,使用脂质体/复方环丙沙星及其它抗感染剂如氨基糖苷类、四环素类及大环内酯类可处理及预防生物恐怖分子所用的细胞内疾病。
制造脂质体/复方药剂的一种方法典型地包括室温进行酒精注入,该温度低于配方所用的类脂的转换温度。脂质体是以小的单层囊(SUV)形式与包含用于胶囊化的生物活性制剂的水或醇溶液混合。将乙醇注入到该混合物中。该混合物立即形成片层状类脂或单层囊泡(MLV)。如果形成片层状类脂,在去除乙醇后可诱导形成单层囊泡(MLV),这可以通过离心、透析或透析过滤等进行喷洒或清洗进行。MLV的直径范围典型地在大约0.1和3.0μm之间。
或者,所采用的类脂也可溶解于乙醇中形成类脂乙醇溶液。将类脂-乙醇溶液注入到水或者含需胶囊化的生物活性制剂分子的醇溶液中。全部制备过程是在类脂的最低相位转变温度以下进行的。该混合物立即形成片层状类脂或单层囊泡(MLV)(10)。片层状类脂在去除乙醇后可诱导形成单层囊泡(MLV),乙醇的去除可以采用离心、透析或透析过滤等进行喷洒或清洗。MLV的直径范围典型地在大约0.1和3.0μm之间。
类脂 | 摩尔比 | 类脂/丁胺卡那霉素,w/w |
DPPC | --- | 1.1 |
类脂 | 摩尔比 | 类脂/丁胺卡那霉素,w/w |
DPPC/DOPG | 9∶1 | 1.0 |
DPPC/DOPG | 7∶1 | 3.9 |
DPPC/DOPG | 1∶1 | 2.8 |
DPPC/DOPG | 1∶2 | 2.7 |
DOPG | --- | 2.6 |
DPPC/胆固醇 | 19∶1 | 1.0 |
DPPC/胆固醇 | 9∶1 | 1.2 |
DPPC/胆固醇 | 4∶1 | 1.7 |
DPPC/胆固醇 | 13∶7 | 2.1 |
DPPC/胆固醇 | 1∶1 | 2.7 |
DPPC/DOPC/胆固醇 | 8.55∶1∶0.45 | 2.0 |
DPPC/DOPC/胆固醇 | 6.65∶1∶0.35 | 3.0 |
DPPC/DOPC/胆固醇 | 19∶20∶1 | 2.5 |
DPPC/DOPG/胆固醇 | 8.55∶1∶0.45 | 3.8 |
DPPC/DOPG/胆固醇 | 6.65∶1∶0.35 | 4.1 |
DPPC/DOPG/胆固醇 | 19∶20∶1 | 4.2 |
DPPC/DOPC/DOPG/胆固醇 | 42∶4∶9∶45 | 3.7 |
DPPC/DOPC/DOPG/胆固醇 | 59∶5∶6∶30 | 3.7 |
多种含有丁胺卡那霉素的配方是根据实施例中的方法制备的,就象下面所总结的一样:
其它制备脂质体/复方抗感染剂的资料可在专利PCT/US03/06847里找到,提交日期为2003年3月5日,其全部资料在此作为参考。
实施例
以下是制备150mL脂质体/复方丁胺卡那霉素的详细描述。
总起始体积=1.5L
乙醇含量=23.5%(v/v)
类脂组成:DPPC/Chol(1∶1摩尔比)
起始[类脂]=7.6mg/ml
起始[丁胺卡那霉素硫酸盐]=57.3mg/ml
最终产品体积=150mL。
I)配制和注入:
7.47克DPPC和3.93克胆固醇在50℃水浴中直接溶于352.5mL乙醇内。85.95g硫酸丁胺卡那霉素直接溶于1147.5mL PBS缓冲液中。然后是用10N氢氧化钠或氢氧化钾将该溶液的pH值滴定至大约为6.8。
将352.5mL乙醇/类脂加入或注入到1147.5mL丁胺卡那霉素/缓冲液中,使起始体积成为1.5L。将乙醇/类脂用一台蠕动泵以30mL/min(也称注入率)的频率抽到丁胺卡那霉素/缓冲液中,然后将其置于反应器中,并在室温以150RPM转速在搅拌器上进行快速搅拌。
将该产品在室温搅拌20-30分钟。
II)透析过滤或″冲洗″的步骤:
将混合器连接于一台蠕动泵及透析过滤盒。透析过滤盒是分子量的cut-off为500千道尔顿的空膜纤维。将产品从反应器中抽出,通过透析过滤盒然后再在室温注入到混合器中。透析过滤盒所产生的反压力约为7磅/平方英寸。通过反压力使单方丁胺卡那霉素和乙醇通过空膜纤维,留下脂质体丁胺卡那霉素(产品)。将该产品在室温冲洗8次。将新配的PBS缓冲液(通过另一台蠕动泵)加入到反应器中,以补偿渗出液,使产品体积保持恒定。
将产品进行浓缩。
出版物和参考文献包括但不限于专利和专利申请,在此全部引入以供参考。任何要求优先权的专利申请在此也与上述出版物和参考文献相同的方式引入以供参考。
本发明的重点在于描述优选的实施方案,本行业普通技术人员显然明确的是,优选的仪器及方法可进行适当改变,而且本发明也能以与这里所特别描述的不同的方式实施。因此,本发明也包括以下权利要求中所定义的提纲和规定范围内的全部改动。
参考文献:
1.Veldhuizen,R.,Nag,K.,Orgeig,S.和Possmayer,F.,The Role ofLipids in Pulmonary Surfactant,Biochim.Biophys.Acta 1408:90-108(1998).
2.Hagwood,S.,Derrick,M.和Poulain,F.,Structure and Properties ofSurfactant Protein B,Biochim.Biophys.Acta 1408:150-160(1998).
3.Johansson,J.,Structure和Properties of Surfactant ProteinC,Biochim.Biophys.Acta 1408:161-172(1998).
4.Ikegami,M.和Jobe,A.H.,Surfactant Protein Metabolism in vivo,Biochim.Biophys.Acta 1408:218-225(1998).
5.Couveur,P.,Fattel,E.和Andremont,A.,Liposomes and Nanoparticlesin the Treatment of Intracellular Bacterial Infections,Pharm.Res.8:1079-1085(1991).
6.Gonzales-Rothi,R.J.,Casace,J.,Straub,L.,和Schreier,H.,Liposomes和Pulmonary Alveolar Macrophages:Functional andMorphologic Interactions,Exp.Lung Res.17:685-705(1991).
7.Swenson,C.E.,Pilkiewicz,F.G.,和Cynamon,M.H.,LiposomalAminoglycosides and TLC-65 Aids Patient Care 290-296(Dec.,1991).
8.Costerton,J.W.,Stewart,P.S.,和Greenberg,E.P.,Bacterial Biofilms:A Common Cause of Persistent Infections,Science 284:1318-1322(1999).
9.Cash,H.A.,Woods,D.E.,McCullough,W.G.,Johanson,J.R.,和Bass,J.A.,A Rat Model of Chronic Respiratory Infection withPseudomonas aeruginosa,American Review of Respiratory Disease 119:453-459(1979).
10.Cantin,A.M.和Woods,D.E.Aerosolized Prolastin SuppressesBacterial Proliferation in a Model of Chronic Pseudomonas aeruginosaLung Infection,Am.J.Respir.Crit.Care Med.160:1130-1135(1999).
11.Ramsey,B.W.,Dorkin,H.L.,Eisenberg,J.D.,Gibson,R.L.,Harwood,I.R.,Kravitz,R.M.,Efficacy of Aerosolized Tobramycin inPatients with cystic Fibrosis.New England J.of Med.328:1740-1746(1993).
12.Mendelman,P.M.,Smith,A.L.,Levy,J.,Weber,A.,Ramsey,B.,Davis,R.L.,Aminoglycoside Penetration,Inactivation,and Efficacy inCystic Pibrosis Sputum,American Review of Respiratory Disease 132:761-765(1985).
13.Price,K.E.,DeFuria,M.D.,Pursiano,T.A.Amikacin,anaminoglycoside with marked activity against antibiotic-resistant clinicalisolates.J Infect Dis 134:S249-261(1976).
14.Damaso,D.,Moreno-Lopez,M.,Martinez-Beltran,J.,Garcia-Iglesias,M.C.Susceptibility of current clinical isolates of Pseudomonasaeruginosa and enteric gram-negative bacilli to Amikacin and otheraminoglycoside antibiotics.J Infect Dis 134:S394-90(1976).
15.Pile,J.C.,Malone,J.D.,Eitzen,E.M.,Friedl和er,A.M.,Anthrax asa potential biological warfare agent.Arch.Intern.Med.158:429-434(1998).
16.Gleiser,C.A.,Berdjis,C.C.,Hartman,H.A.,& Glouchenour,W.S.,Pathology of experimental respiratory anthrax in Macaca mulatta.Brit.J.Exp.Path.,44:416-426(1968).
Claims (20)
1.脂质体抗感染制剂的用于制备一种药物的用途,其中所述药物用于处理或改善患者肺部感染,包括通过肺部给予患者一种有效剂量的脂质体抗感染制剂,其中所述的脂质体抗感染制剂包括类脂组分和抗感染剂,其中所述的类脂组分包括甾醇和磷脂酰胆碱,并且所述的类脂与抗感染剂的重量比为2.5∶1以下,其中所述的抗感染剂是氨基葡糖苷。
2.权利要求1所述的用途,其中的给药方案是每天一次或更少。
3.权利要求1所述的用途,其中的给药方案是每2天一次或更少。
4.权利要求1所述的用途,其中的给药方案是每3天一次或更少。
5.权利要求1所述的用途,其中的抗感染剂是丁胺卡那霉素。
6.权利要求5所述的用途,其中的给药方案是每天一次或更少。
7.权利要求5所述的用途,其中的给药方案是每2天一次或更少。
8.权利要求5所述的用途,其中的给药方案是每3天一次或更少。
9.权利要求1所述的用途,其中所需处理或改善的感染是一种假单胞菌,葡萄球菌,耐甲氧苯青霉素金黄色葡萄球菌(MRSA),链球菌,大肠杆菌,克雷伯氏菌属,肠杆菌属,沙雷式菌属,嗜血杆菌,鼠疫耶尔森(氏)菌,类鼻疽伯克霍尔德氏菌,洋葱伯克霍尔德菌,唐菖蒲伯克霍尔德菌,multivorans伯克霍尔德氏菌,越南伯克霍尔德氏菌,结核分支杆菌,鸟分枝杆菌复合体(MAC),堪萨斯分枝杆菌,蟾分枝杆菌,海分枝杆菌,溃疡分枝杆菌,或者偶发分枝杆菌复合体感染。
10.权利要求1所述的用途,其中所需处理或改善的感染是一种假单胞菌感染。
11.权利要求1所述的用途,其中所需处理或改善的感染是一种绿脓假单胞菌感染。
12.权利要求1所述的用途,其中的有效量是指在肺感染症状已经出现后可有效处理或改善的量。
13.权利要求1所述的用途,其中的抗感染剂是硫酸丁胺卡那霉素。
14.权利要求1所述的用途,其中所述的磷脂酰胆碱是DPPC,所述的甾醇是胆固醇。
15.脂质体丁胺卡那霉素制剂的用于制备一种药物的用途,其中所述药物用于处理或改善患者肺部感染,包括通过肺部给予患者一种有效剂量的脂质体抗感染制剂,其中所述的脂质体丁胺卡那霉素制剂包括类脂组分和丁胺卡那霉素,其中所述的类脂组分包括胆固醇和DPPC,并且所述的类脂与抗感染剂的重量比为2.5∶1以下。
16.权利要求15所述的用途,其中所述的丁胺卡那霉素以硫酸丁胺卡那霉素的形式提供。
17.权利要求1至16任意一项所述的用途,其中所述的患者是囊性纤维变性患者。
18.权利要求15或16所述的用途,其中所述的DPPC与所述的甾醇的摩尔比为约1∶1。
19.权利要求15或16所述的用途,其中所述的类脂与所述的丁胺卡那霉素的重量比为1.1∶1或更低。
20.权利要求9所述的用途,其中所需处理或改善的感染是为少动假单胞菌、恶臭假单胞菌、萤光假单胞菌和食酸假单胞菌,肺炎链球菌感染。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42192302P | 2002-10-29 | 2002-10-29 | |
US60/421,923 | 2002-10-29 | ||
PCT/US2003/034240 WO2004110346A2 (en) | 2002-10-29 | 2003-10-29 | Sustained release of antiinfectives |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1747738A CN1747738A (zh) | 2006-03-15 |
CN1747738B true CN1747738B (zh) | 2010-11-24 |
Family
ID=33551200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2003801065342A Expired - Lifetime CN1747738B (zh) | 2002-10-29 | 2003-10-29 | 缓释抗感染剂 |
Country Status (19)
Country | Link |
---|---|
US (10) | US7544369B2 (zh) |
EP (4) | EP2363114B1 (zh) |
JP (6) | JP5118302B2 (zh) |
KR (3) | KR101301653B1 (zh) |
CN (1) | CN1747738B (zh) |
AU (1) | AU2003304204B2 (zh) |
BR (1) | BR0315868A (zh) |
CA (1) | CA2504317C (zh) |
DK (2) | DK2363114T3 (zh) |
ES (4) | ES2831305T3 (zh) |
HK (2) | HK1162303A1 (zh) |
HU (1) | HUE025491T2 (zh) |
IL (2) | IL168279A (zh) |
MX (2) | MXPA05004580A (zh) |
NZ (1) | NZ540087A (zh) |
PT (2) | PT1581236E (zh) |
SI (2) | SI2363114T1 (zh) |
WO (1) | WO2004110346A2 (zh) |
ZA (1) | ZA200504281B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402845B2 (en) | 2005-12-08 | 2016-08-02 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
CA2477979A1 (en) * | 2002-03-05 | 2003-09-18 | Transave, Inc. | An inhalation system for treatment of intracellular infections |
US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
KR101301653B1 (ko) * | 2002-10-29 | 2013-08-30 | 트랜세이브, 인코포레이티드 | 항감염제의 지속적인 방출 |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US20040087527A1 (en) * | 2002-10-31 | 2004-05-06 | Day Brian J. | Methods for treatment of thiol-containing compound deficient conditions |
US20080221029A1 (en) * | 2002-10-31 | 2008-09-11 | Regents Of The University Of Colorado | Methods for treatment of thiol-containing compound deficient conditions |
GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
KR101424518B1 (ko) * | 2005-09-29 | 2014-08-06 | 노바르티스 아게 | 항생제 제형, 단위 투여체, 키트 및 방법 |
AU2013206401B2 (en) * | 2005-09-29 | 2016-06-23 | Novartis Ag | Antibiotic formulations, unit doses, kits, and methods |
US20080118489A1 (en) * | 2005-10-21 | 2008-05-22 | The Board Of Trustees Of The University Of Illinois | Charge-Modified Lysozyme Antimicrobial Compositions, Surfactants, and Methods for Infections and Cystic Fibrosis |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
JP5600432B2 (ja) * | 2006-04-06 | 2014-10-01 | インスメッド, インコーポレイテッド | コアセルベート化誘導リポソーム被包法及びその調合物 |
US20080131497A1 (en) * | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
AU2007306344B2 (en) * | 2006-10-11 | 2014-01-16 | Laboratoires Smb S.A. | Pharmaceutical anti-infective composition for inhalation. |
AU2012211514B2 (en) * | 2006-10-24 | 2014-07-31 | Aradigm Corporation | Concentrated, inhalable ciprofloxacin formulation |
US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8119156B2 (en) | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
MX2010004389A (es) * | 2007-10-23 | 2010-05-20 | Transave Inc | Formulaciones de vancomicina liposomales. |
SI2716157T1 (sl) | 2008-12-08 | 2016-10-28 | Gilead Connecticut, Inc., c/o Gilead Sciences, Inc. | Imidazopirazinski Syk-inhibitorji |
ES2744541T3 (es) | 2008-12-08 | 2020-02-25 | Gilead Connecticut Inc | Inhibidores de imidazopirazina Syk |
US20100239626A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Propanediol delivery systems |
US20100239650A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Isothiazolin biodelivery systems |
US20100239630A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Phosphonium salts delivery systems |
US20100239627A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Quarternary ammonium salts delivery systems |
US20100239651A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Nitrilopropionamide delivery systems |
KR102277921B1 (ko) | 2012-05-21 | 2021-07-14 | 인스메드 인코포레이티드 | 폐 감염을 치료하기 위한 시스템 |
JP2015530387A (ja) | 2012-09-04 | 2015-10-15 | エライゾン ファーマシューティカルズ, エルエルシー | 脂質複合体化シスプラチンによる肺癌の再発防止 |
EP3581186A1 (en) | 2012-11-29 | 2019-12-18 | Insmed Incorporated | Stabilized vancomycin formulations |
CN103055966B (zh) * | 2012-12-26 | 2015-01-14 | 北京航空航天大学 | 基于分支型氧化铝纳米通道薄膜的纳流体二极管器件 |
US9987227B2 (en) | 2013-10-22 | 2018-06-05 | Aradigm Corporation | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile |
CN103735508B (zh) * | 2013-12-27 | 2016-11-09 | 上海上药新亚药业有限公司 | 多粘菌素脂质体及其制备工艺 |
US9532986B2 (en) | 2014-04-08 | 2017-01-03 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
PL3142643T3 (pl) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Sposoby leczenia zakażeń płuc prątkami niegruźliczymi |
KR101695744B1 (ko) * | 2014-10-16 | 2017-01-12 | 한국생명공학연구원 | 시클로피록스와 폴리믹신 b 조합을 이용한 병원성 그램-음성 박테리아 제어 방법 |
CN104888222A (zh) * | 2015-06-09 | 2015-09-09 | 深圳市健元医药科技有限公司 | 治疗复合感染的药物组合物及其制备方法 |
WO2018090004A2 (en) * | 2016-11-14 | 2018-05-17 | The University Of North Carolina At Chapel Hill | Tuberculosis therapeutic compounds and methods |
EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS |
US11534399B2 (en) | 2018-04-23 | 2022-12-27 | Inspirmed Corp. | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
EP3927708A1 (en) | 2019-02-22 | 2021-12-29 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
EP3906946A1 (en) | 2020-05-04 | 2021-11-10 | EK Biosciences GmbH | Antipathogen vesicle |
TW202302072A (zh) * | 2021-03-18 | 2023-01-16 | 國立臺灣大學 | 用於親水帶電化合物的脂質奈米顆粒遞送系統 |
CN117838672B (zh) * | 2024-03-07 | 2024-05-10 | 山东第二医科大学 | 一种替米考星/g型褐藻寡糖雾化吸入纳米混悬液及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662929A (en) * | 1994-12-23 | 1997-09-02 | Universite De Montreal | Therapeutic liposomal formulation |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH624011A5 (zh) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
GB2046092B (en) * | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
HU184141B (en) * | 1979-12-27 | 1984-07-30 | Human Oltoanyagtermelo | Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof |
US4451447A (en) * | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
ATE18353T1 (de) | 1981-07-02 | 1986-03-15 | Hoffmann La Roche | Verfahren zur herstellung von liposomenloesungen. |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4981692A (en) * | 1983-03-24 | 1991-01-01 | The Liposome Company, Inc. | Therapeutic treatment by intramammary infusion |
US5169637A (en) * | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
GB8308174D0 (en) | 1983-03-24 | 1983-05-05 | Ae Plc | Squeeze casting of articles |
US4515736A (en) | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
CA1237670A (en) * | 1983-05-26 | 1988-06-07 | Andrew S. Janoff | Drug preparations of reduced toxicity |
CA1237671A (en) * | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
GB8322178D0 (en) | 1983-08-17 | 1983-09-21 | Sterwin Ag | Preparing aerosol compositions |
US4721612A (en) | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
SE8403905D0 (sv) * | 1984-07-30 | 1984-07-30 | Draco Ab | Liposomes and steroid esters |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
ATE78158T1 (de) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
US5409704A (en) * | 1985-06-26 | 1995-04-25 | The Liposome Company, Inc. | Liposomes comprising aminoglycoside phosphates and methods of production and use |
US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
JPH0665648B2 (ja) * | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
US5041278A (en) | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
US5041581A (en) * | 1985-10-18 | 1991-08-20 | The University Of Texas System Board Of Regents | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
US4833134A (en) * | 1986-08-19 | 1989-05-23 | Takeda Chemical Industries, Ltd. | Cephem compounds |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US4933121A (en) * | 1986-12-10 | 1990-06-12 | Ciba Corning Diagnostics Corp. | Process for forming liposomes |
US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
IL97538A (en) * | 1986-12-23 | 1995-03-15 | Liposome Co Inc | Multilayer liposomes containing guanidino aminoglycosides and their preparation |
US5723147A (en) * | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
US4895452A (en) * | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
CA1335348C (en) | 1988-03-04 | 1995-04-25 | Yasuaki Ogawa | Liposome composition |
US5269979A (en) * | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
BE1001869A3 (fr) * | 1988-10-12 | 1990-04-03 | Franz Legros | Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine. |
US4952405A (en) * | 1988-10-20 | 1990-08-28 | Liposome Technology, Inc. | Method of treating M. avium infection |
US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5820848A (en) * | 1990-01-12 | 1998-10-13 | The Liposome Company, Inc. | Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7908791A (en) | 1990-05-08 | 1991-11-27 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
US5770563A (en) * | 1991-12-06 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
WO1993012240A1 (en) | 1991-12-17 | 1993-06-24 | The Regents Of The University Of California | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
US5958449A (en) * | 1992-12-02 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for bacterial infections |
AU3244393A (en) | 1992-12-02 | 1994-06-22 | Vestar, Inc. | Antibiotic formulation and process |
US5665383A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
CA2159596C (en) * | 1993-04-02 | 2002-06-11 | Royden Coe | Method of producing liposomes |
US5759571A (en) * | 1993-05-11 | 1998-06-02 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for drug resistant infections |
US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
WO1995016464A1 (en) * | 1993-12-14 | 1995-06-22 | Johns Hopkins University School Of Medicine | Controlled release of pharmaceutically active substances for immunotherapy |
US5610198A (en) * | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
US5550109A (en) * | 1994-05-24 | 1996-08-27 | Magainin Pharmaceuticals Inc. | Inducible defensin peptide from mammalian epithelia |
US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
AR002009A1 (es) | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
US5800833A (en) * | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
US5855610A (en) * | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5900184A (en) * | 1995-10-18 | 1999-05-04 | Lord Corporation | Method and magnetorheological fluid formulations for increasing the output of a magnetorheological fluid device |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US6132765A (en) * | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
ES2201296T3 (es) * | 1996-04-26 | 2004-03-16 | Genaera Corporation | Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores. |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
DK0929293T3 (da) * | 1996-08-23 | 2004-02-02 | Sequus Pharm Inc | Liposomer indeholdende en cisplatinforbindelse |
US5837282A (en) * | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
US6451784B1 (en) * | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
JP2001513078A (ja) * | 1996-12-30 | 2001-08-28 | バテル・メモリアル・インスティテュート | 吸入により新生物を治療する製剤とその方法 |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
KR20010031363A (ko) * | 1997-10-22 | 2001-04-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
US6051251A (en) * | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
AU1656799A (en) * | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US6509323B1 (en) * | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
IL143046A0 (en) * | 1998-11-12 | 2002-04-21 | Pilkiewicz Frank G | An inhalation system |
US6855296B1 (en) * | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
DE69938875D1 (zh) | 1998-11-13 | 2008-07-17 | William A Heriot | |
SI20959A (sl) * | 1998-12-17 | 2003-02-28 | Pathogenesis Corporation | Metoda za zdravljenje hudega kroničnega bronhitisa (bronhiektazije) z aerosoliziranimi antibiotiki |
US6211162B1 (en) * | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
US6613352B2 (en) * | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
EP1206234A4 (en) * | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
IL150027A0 (en) * | 1999-12-04 | 2002-12-01 | Res Dev Foundation | Carbon dioxide enhancement of inhalation therapy |
US6968840B2 (en) * | 2000-05-05 | 2005-11-29 | Aerogen, Inc. | Methods and systems for operating an aerosol generator |
EP1292314A2 (en) * | 2000-05-23 | 2003-03-19 | The Trustees of Columbia University in the City of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans |
US6338859B1 (en) * | 2000-06-29 | 2002-01-15 | Labopharm Inc. | Polymeric micelle compositions |
US6521736B2 (en) * | 2000-09-15 | 2003-02-18 | University Of Massachusetts | Amphiphilic polymeric materials |
US6497901B1 (en) * | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
EP1203614A1 (de) * | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
CA2437555A1 (en) * | 2001-02-01 | 2002-08-08 | Yiyu Zou | Stabilised polymeric aerosols for pulmonary gene delivery |
US20030060451A1 (en) * | 2001-05-29 | 2003-03-27 | Rajneesh Taneja | Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin |
EP1269993A1 (en) * | 2001-06-21 | 2003-01-02 | Applied NanoSystems B.V. | Delivery of small hydrophilic molecules packaged into lipid vesicles |
WO2003000236A1 (en) * | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particles with improved solubilization capacity |
WO2003015698A2 (en) * | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
CA2456746A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
US20030096774A1 (en) * | 2001-11-21 | 2003-05-22 | Igor Gonda | Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
US7368102B2 (en) * | 2001-12-19 | 2008-05-06 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
CA2477979A1 (en) * | 2002-03-05 | 2003-09-18 | Transave, Inc. | An inhalation system for treatment of intracellular infections |
AU2003302314A1 (en) * | 2002-08-02 | 2004-07-09 | Transave, Inc. | Platinum aggregates and process for producing the same |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
KR101301653B1 (ko) * | 2002-10-29 | 2013-08-30 | 트랜세이브, 인코포레이티드 | 항감염제의 지속적인 방출 |
US7968115B2 (en) * | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
GB2388581A (en) * | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
DE102005034403B3 (de) * | 2005-07-22 | 2007-02-22 | Airbus Deutschland Gmbh | Führungsmittel für eine Vorrichtung zur Herstellung von Faservorformlingen im TFP-Verfahren für Verbundbauteile |
KR100705981B1 (ko) * | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물 |
CA2838111C (en) * | 2005-12-08 | 2016-01-19 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
JP5600432B2 (ja) * | 2006-04-06 | 2014-10-01 | インスメッド, インコーポレイテッド | コアセルベート化誘導リポソーム被包法及びその調合物 |
US8119156B2 (en) * | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) * | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) * | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
AU2011278693B2 (en) * | 2010-07-12 | 2015-02-19 | Xellia Pharmaceuticals Aps | Treatment of lung infections by administration of Tobramycin by aerolisation |
-
2003
- 2003-10-29 KR KR1020057007679A patent/KR101301653B1/ko active IP Right Grant
- 2003-10-29 HU HUE11159754A patent/HUE025491T2/en unknown
- 2003-10-29 NZ NZ540087A patent/NZ540087A/en not_active IP Right Cessation
- 2003-10-29 EP EP20110159754 patent/EP2363114B1/en not_active Revoked
- 2003-10-29 EP EP14183066.1A patent/EP2823820B1/en not_active Expired - Lifetime
- 2003-10-29 KR KR1020137010499A patent/KR101424980B1/ko active IP Right Grant
- 2003-10-29 PT PT38169900T patent/PT1581236E/pt unknown
- 2003-10-29 ES ES18176134T patent/ES2831305T3/es not_active Expired - Lifetime
- 2003-10-29 PT PT111597548T patent/PT2363114E/pt unknown
- 2003-10-29 EP EP03816990.0A patent/EP1581236B1/en not_active Expired - Lifetime
- 2003-10-29 CA CA2504317A patent/CA2504317C/en not_active Expired - Lifetime
- 2003-10-29 WO PCT/US2003/034240 patent/WO2004110346A2/en active Application Filing
- 2003-10-29 MX MXPA05004580A patent/MXPA05004580A/es active IP Right Grant
- 2003-10-29 ES ES11159754.8T patent/ES2539591T3/es not_active Expired - Lifetime
- 2003-10-29 BR BR0315868-3A patent/BR0315868A/pt not_active Application Discontinuation
- 2003-10-29 ES ES03816990.0T patent/ES2439727T3/es not_active Expired - Lifetime
- 2003-10-29 KR KR1020147005780A patent/KR101504616B1/ko active IP Right Grant
- 2003-10-29 DK DK11159754.8T patent/DK2363114T3/da active
- 2003-10-29 MX MX2013013982A patent/MX353044B/es unknown
- 2003-10-29 DK DK03816990.0T patent/DK1581236T3/da active
- 2003-10-29 EP EP18176134.7A patent/EP3427742B1/en not_active Expired - Lifetime
- 2003-10-29 SI SI200332430T patent/SI2363114T1/sl unknown
- 2003-10-29 AU AU2003304204A patent/AU2003304204B2/en not_active Expired
- 2003-10-29 SI SI200332321T patent/SI1581236T1/sl unknown
- 2003-10-29 JP JP2005500829A patent/JP5118302B2/ja not_active Expired - Lifetime
- 2003-10-29 US US10/696,389 patent/US7544369B2/en active Active
- 2003-10-29 CN CN2003801065342A patent/CN1747738B/zh not_active Expired - Lifetime
- 2003-10-29 ES ES14183066.1T patent/ES2686361T3/es not_active Expired - Lifetime
-
2005
- 2005-04-28 IL IL168279A patent/IL168279A/en active IP Right Grant
- 2005-05-25 ZA ZA200504281A patent/ZA200504281B/xx unknown
-
2009
- 2009-04-15 US US12/424,177 patent/US20100068257A1/en not_active Abandoned
-
2011
- 2011-01-06 JP JP2011001318A patent/JP5411878B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-07 HK HK12102361.3A patent/HK1162303A1/zh not_active IP Right Cessation
- 2012-03-07 HK HK15102375.4A patent/HK1201749A1/zh not_active IP Right Cessation
-
2013
- 2013-08-12 JP JP2013167610A patent/JP5684343B2/ja not_active Expired - Lifetime
-
2014
- 2014-10-31 JP JP2014222230A patent/JP2015025016A/ja not_active Withdrawn
- 2014-12-11 IL IL236190A patent/IL236190B/en active IP Right Grant
-
2016
- 2016-02-19 JP JP2016029641A patent/JP6130946B2/ja not_active Expired - Lifetime
- 2016-04-07 US US15/093,180 patent/US20160271125A1/en not_active Abandoned
- 2016-10-20 US US15/299,101 patent/US20170100420A1/en not_active Abandoned
-
2017
- 2017-07-06 JP JP2017132617A patent/JP2017171688A/ja not_active Withdrawn
- 2017-12-15 US US15/843,531 patent/US20180169124A1/en not_active Abandoned
-
2018
- 2018-04-26 US US15/963,659 patent/US20180318326A1/en not_active Abandoned
- 2018-07-12 US US16/033,690 patent/US20180318327A1/en not_active Abandoned
- 2018-11-09 US US16/185,384 patent/US20190142854A1/en not_active Abandoned
-
2019
- 2019-02-01 US US16/264,865 patent/US20190160087A1/en not_active Abandoned
-
2021
- 2021-03-10 US US17/197,867 patent/US20220016150A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662929A (en) * | 1994-12-23 | 1997-09-02 | Universite De Montreal | Therapeutic liposomal formulation |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9402845B2 (en) | 2005-12-08 | 2016-08-02 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9511082B2 (en) | 2005-12-08 | 2016-12-06 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9549939B2 (en) | 2005-12-08 | 2017-01-24 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US9549925B2 (en) | 2005-12-08 | 2017-01-24 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1747738B (zh) | 缓释抗感染剂 | |
JP6125676B2 (ja) | 徐放性抗感染剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INCEMADE CORP. Free format text: FORMER OWNER: TRANSAVE INC. Effective date: 20130628 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130628 Address after: American Virginia Patentee after: Ince Dmitry Co. Address before: New jersey, USA Patentee before: TRANSAVE, Inc. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20101124 |